Treatment of ACuTe Coronary Syndromes With Low-dose colchICine (TACTIC): a Randomised, Double-blinded, Placebo-controlled, Multicentric Trial
Status: Recruiting
Location: See location...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY
This trial is designed to evaluate whether low-dose colchicine, in addition to standard treatment recommended by guidelines, further reduces the risk of major adverse cardiovascular events in patients with acute coronary syndromes (ACS) through a prospective, randomized, double-blind, placebo-controlled clinical trial.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:
• Age ≥ 18 years;
• Definite diagnosis of ACS;
• Ability and willingness to provide written informed consent
Locations
Other Locations
China
Beijing Anzhen Hospital
RECRUITING
Beijing
Contact Information
Primary
Yujie Zhou, PhD, MD
azzyj12@163.com
8613901330652
Backup
Xiaoteng Ma, MD
maxiaotengai@163.com
8618810616459
Time Frame
Start Date: 2024-09-02
Estimated Completion Date: 2028-06
Participants
Target number of participants: 6574
Treatments
Experimental: Colchicine group
Patients are randomized within 48 hours after diagnosis of ACS, and on the day of randomization, eligible patients undergo standard treatment plus colchicine (0.5mg qd from 1st month to 12th month).
Placebo_comparator: Placebo group
Patients are randomized within 48 hours after diagnosis of ACS, and on the day of randomization, eligible patients undergo standard treatment plus placebo (1 tablet qd from 1st month to 12th month).
Related Therapeutic Areas
Sponsors
Leads: Beijing Anzhen Hospital